What NICE actually says about pregnancy and MS

NICE guideline NG220 on multiple sclerosis in adults contains an unusually direct list of things clinicians are asked to tell people with MS who are planning a family. Recommendation 1.2.13 says to explain that MS "should not stop them from planning a family", and then sets out the specifics:

"that fertility is not affected by MS"
"that pregnancy can be well managed in people with MS"
"that pregnancy does not increase the risk of disease progression"
"that relapses may decrease during pregnancy and may increase 3 to 6 months after childbirth before returning to pre-pregnancy rates"
"that birth options and pain relief choices available (including epidurals) should not be affected by MS"
"that breastfeeding is safe unless the person with MS is taking certain disease-modifying therapies"

That last point about epidurals matters, because the belief that MS rules out regional anaesthesia is persistent and wrong. If you are told otherwise on a labour ward, this recommendation is the one to point at.

The postnatal window is the risk, not the pregnancy

The pattern NICE describes is worth planning around rather than simply knowing. Relapse activity tends to fall as pregnancy progresses and then rise in the first few months after birth before settling back to your previous baseline. That means the months when you are most sleep-deprived and least able to attend appointments are also the months when relapse is most likely.

The practical response is to agree before birth who is reviewing you, when, and how you reach your MS team quickly if something changes. Being able to distinguish a relapse from ordinary postnatal exhaustion is much easier when someone who knows your MS is looking.

Disease-modifying therapy is decided before conception

NG220 recommendation 1.2.12 tells clinicians to make sure people taking disease-modifying therapies "understand that they should tell their healthcare professionals straight away if they are trying to become pregnant or if they become pregnant". Recommendation 1.2.11 asks clinicians to raise family plans soon after diagnosis and at regular intervals, precisely so this is not a rushed decision.

The MS Society sets out the practical shape of that decision. Some disease-modifying therapies are not considered safe in pregnancy, and it names fingolimod and teriflunomide as examples to discuss stopping before trying to conceive. It also notes that where a therapy is stopped for pregnancy, the washout period varies: "depending on the drug, that could take between one and 12 months". That range is the reason this is a preconception conversation, not a first-trimester one.

This page names drugs and does not give doses. Which therapy you are on, how active your MS is, and how long a washout you would need are all individual, and the balance of benefit and risk, as the MS Society puts it, "will be a personal one".

Relapses during pregnancy

Relapses can still happen while you are pregnant. Steroids are the usual treatment for a significant relapse and are used in pregnancy where the relapse warrants it; the decision is made by your neurologist with your obstetric team, and again this page names the treatment without dosing it. A relapse is not the same as a temporary worsening of existing symptoms caused by heat, infection or fatigue, all of which are more likely in pregnancy, so a urine infection is checked for before anything else.

Your antenatal care

MS on its own does not usually change the routine schedule set out in NICE guideline NG201. What it adds is planning. Symptoms that are already present, particularly bladder dysfunction, fatigue, spasticity and reduced mobility, tend to be amplified by late pregnancy, and each has a practical answer if raised early: urine testing and bladder management, physiotherapy input, mobility aids, and a realistic look at positions for labour.

NG220 also lists vitamin D and folic acid supplementation before and during pregnancy among the things to discuss, pointing to NICE's separate guidance on those. Mental health is worth naming too; NICE guideline CG192 asks for it to be discussed at booking, and living with a long-term neurological condition is a recognised reason to look for it rather than wait.

Labour and birth

NICE guideline NG121 covers intrapartum care where an existing medical condition is present and asks for a multidisciplinary plan agreed in advance. For MS the specific questions are mobility and positioning, bladder management in labour, and whether reduced abdominal muscle power affects the pushing stage. None of those makes vaginal birth unlikely; they change the preparation.

The NHS pages on multiple sclerosis describe the underlying condition and its usual course, and are a reasonable starting point if the person supporting you is unfamiliar with MS.

Breastfeeding

NG220 says breastfeeding is safe unless you are taking certain disease-modifying therapies. The MS Society is more specific about which, noting for example that the Association of British Neurologists advises that breastfeeding should be encouraged during treatment with beta interferons and glatiramer acetate, while some other therapies should be avoided. Because these positions are updated as evidence accumulates, the answer for your specific therapy should come from your neurologist rather than from a page written at a fixed point in time.

Will my child get MS?

NG220 lists "the risk of the child developing MS" among the things to discuss, without attaching a number, and that restraint is deliberate. MS is not inherited in a single-gene pattern; risk in relatives is higher than in the general population but remains low in absolute terms, and published estimates vary by population and study design. If you want a figure, ask your neurologist for one with its source attached, rather than taking the confident percentages that circulate online. What is not in doubt is that having MS is not a reason to be discouraged from having children, which is what recommendation 1.2.13 says in as many words.

Multiple Sclerosis in Pregnancy